A new video on managing uveitis, presented by Dr Sophia Zagora, is now available under Clinician Resources
JAFA’ s 2023 national IMPACT Study report documents the significant burden of pain, physical limitations, mental and emotional distress, social isolation, poor quality of life, lost educational opportunity, and financial costs attributable to juvenile idiopathic arthritis and related childhood rheumatic diseases.
The Australian Juvenile Arthritis Registry (AJAR) is a minimum dataset registry for 0-24yr olds with juvenile idiopathic arthritis and related childhood rheumatic diseases. It was initiated by JAFA and established in 2023 under a three-way partnership between JAFA, the Australian Paediatric Rheumatology Group, and the A3BC Arthritis and Autoimmune Biobank. This Inaugural Report (2024) provides information on the first 300 registrants.
This 2023 AIHW report presents information on the estimated prevalence of juvenile idiopathic arthritis, its treatment, management, outcomes, economic impact and burden of disease. It also contains information about the paediatric rheumatology workforce.
This 2023 article, by Australian paediatric rheumatologists, describes the diagnosis, subtypes and medical management of juvenile idiopathic arthritis. It also provides an overview of available medications and emphasises the improvements in patient outcomes in recent years.
Timely diagnosis of JIA ensures early treatment to minimize long-term joint damage and disability. This Australian study, led by Dr Amy Von Huben, investigated the impact of earlier diagnosis of JIA and showed that quality of life was better and annual healthcare costs were reduced by over $10,000 per child due to reduced hospitalisations for pain, inflammation, and investigative procedures.
This 2023 document by the APRG outlines currently recommended standards for the clinical care for children and young people with juvenile idiopathic arthritis. It outlines guiding principles and quality statements in seven different domains of care.